Ketobemidone

Revision as of 19:48, 26 May 2021 by >IJUSTPOPPEDAXAN (Added references)
Summary sheet: Ketobemidone


Ketobemidone (also known by the brand names Ketogan, and Ketorax) is a synthetic opioid substance of the piperidine class. It is used to treat severe pain (like cancer pain, postoperative pain, gallstone pain, and kidney pain).

Ketobemidone
Chemical Nomenclature
Common names Cliradon, Cymidon, Ketogan, Ketorax
Substitutive name Ketobemidone
Systematic name 1-[4-(3-Hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-one
Class Membership
Psychoactive class Opioid
Chemical class Piperidine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Bioavailability 17% - 62%[1]
Threshold 2.5 mg
Light 2.5 - 5 mg
Common 10 - 15 mg
Strong 15 - 25 mg
Heavy 25 mg +
Duration
Total 3 - 5.5 hours
Onset 10 - 30 minutes




Rectal
Dosage
Bioavailability 44%[2]
Threshold 2 - mg
Light 2 - 4 mg
Common 7.5 - 11.5 mg
Strong 11.5 - 20 mg
Heavy 20 mg +
Duration
Total x"x" is not a number. - y"y" is not a number. hours
Onset x"x" is not a number. - y"y" is not a number. minutes




Intravenous
Dosage
Bioavailability 100%[citation needed]
Threshold x"x" is not a number. - mg
Light x"x" is not a number. - y"y" is not a number. mg
Common x"x" is not a number. - y"y" is not a number. mg
Strong x"x" is not a number. - y"y" is not a number. mg
Heavy x"x" is not a number. mg +
Duration
Total 2 - 3 hours
Onset 5 - 10 seconds

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
MAOIs
Nitrous
PCP
Alcohol
Benzodiazepines
DXM
GHB
GBL
Ketamine
MXE
Tramadol
Grapefruit
MAOIs
Serotonin releasers
SSRIs
5-HTP


History and culture

Chemistry

Pharmacology

Subjective effects

Toxicity and harm potential

Tolerance and addiction potential

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Alcohol - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely
  • Stimulants - Stimulants increase respiration rate which allows for a higher dose of opiates than would otherwise be used. If the stimulant wears off first then the opiate may overcome the user and cause respiratory arrest.
  • Benzodiazepines - Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position blackouts/memory loss likely.
  • DXM - Generally considered to be toxic. CNS depression, difficulty breathing, heart issues, and liver toxicity have been observed. Additionally if one takes DXM, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.
  • GHB/GBL - The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position
  • Ketamine - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
  • MAOIs - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.
  • MXE - MXE can potentiate the effects of opioids but also increases the risk of respiratory depression and organ toxicity.
  • Nitrous - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are common.
  • PCP - PCP may reduce opioid tolerance, increasing the risk of overdose.
  • Tramadol - Increased risk of seizures. Tramadol itself is known to induce seizures and it may have additive effects on seizure threshold with other opioids. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present.
  • Grapefruit - While grapefruit is not psychoactive, it may affect the metabolism of certain opioids. Tramadol, oxycodone, and fentanyl are all primarily metabolized by the enzyme CYP3A4, which is potently inhibited by grapefruit juice[3]. This may cause the drug to take longer to clear from the body. it may increase toxicity with repeated doses. Methadone may also be affected[3]. Codeine and hydrocodone are metabolized by CYP2D6. People who are on medicines that inhibit CYP2D6, or that lack the enzyme due to a genetic mutation will not respond to codeine as it can not be metabolized into its active product: morphine.

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

See also


References

  1. https://bok.fass.se/LIF/product?userType=0&nplId=19930507000075
  2. Wikipedia contributors. (2021, March 28). Ketobemidone. In Wikipedia, The Free Encyclopedia. Retrieved 20:57, May 28, 2021, from https://en.wikipedia.org/w/index.php?title=Ketobemidone&oldid=1014750378
  3. 3.0 3.1 Ershad, M., Cruz, M. D., Mostafa, A., Mckeever, R., Vearrier, D., Greenberg, M. I. (March 2020). "Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance". Journal of Addiction Medicine. 14 (2): 172–174. doi:10.1097/ADM.0000000000000535. ISSN 1932-0620. 
  4. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.